BioCentury
ARTICLE | Company News

Antisense, Teva deal

February 25, 2008 8:00 AM UTC

Antisense granted Teva an exclusive, worldwide license to develop and market ATL1102 to treat relapsing-remitting multiple sclerosis (MS). Antisense will receive $2 million up front and is eligible f...